Toxicology, 65 (1991) 353—356
Elsevier Scientific Publishers Ireland Ltd.

TOXICOLOGY

SUBJECT INDEX

Volume 65 (1990/91)

acrylic acid esters, inhalation, acrylonitrile, total and non-protein sulfhydryls, blood glucose, chemical reactivity, 209
acrylonitrile, inhalation, acrylic acid esters, total and non-protein sulfhydryls, blood glucose, chemical reactivity, 209
acute toxicity, 2,3,7,8,-tetrachlorodibenzo-*p*-dioxin, species differences, total body fat content, 97
adduct, benzo[*a*]pyrene, carcinogen, chromatography, hemoglobin, in vitro metabolism, 109
adenosine triphosphatase, diabetes mellitus, aluminum, calcium, calmodulin, sarcoplasmic reticulum, 137
aluminum, diabetes mellitus, calcium, calmodulin, adenosine triphosphatase, sarcoplasmic reticulum, 137
3-amino-1-hydroxypropylidene-1,1-bisphosphonate, pamidronate, treatment of metabolic bone disorders, nephrotoxicity, pharmacokinetics, enzymuria, 179
amiodarone, desethylamiodarone, placental-transfer, fetotoxicity, birth weight, 259
animals, risk assessment, experimental carcinogens, low dose extrapolation, reproducibility, methylene chloride, 75
animal model, hyperreactive airways, pulmonary hypersensitivity, histamine challenge, guinea pig, ovalbumin, 283
astrocytes, lead, disulfiram, GFA, image analysis, brain development, 333
astroglia, glutamine synthetase activity, inorganic lead, lead-exposed rats, 295

benoxaprofen, cytochromes *P*450I and *P*450IV, computer optimised molecular parametric analysis for chemical toxicity, quantitative structure-activity relationship, hepatotoxicity, phototoxicity, 33
benzo[*a*]pyrene, adduct, carcinogen, chromatography, hemoglobin, in vitro metabolism, 109
birth weight, amiodarone, desethylamiodarone, placental-transfer, fetotoxicity, 259
blood glucose, inhalation, acrylonitrile, acrylic acid esters, total and non-protein sulfhydryls, chemical reactivity, 209
brain development, lead, disulfiram, astrocytes, GFA, image analysis, 333
buthionine sulfoximine, UDP-glucuronosyltransferases, glutathione *S*-transferase, induction, 149

cadmium, diethyldithiocarbamate, hepatocytes, lead, mercury, 23
cadmium, osteosarcoma cells, ROS 117/2.8 cells, metallothionein, 169
cadmium, selenium, gluconeogenic precursors, rat hepatocytes, 161
cadmium-metallothionein, nephrotoxicity, distribution, pregnant rat, 223
calcium, diabetes mellitus, aluminum, calmodulin, adenosine triphosphatase, sarcoplasmic reticulum, 137
calmodulin, diabetes mellitus, aluminum, calcium, adenosine triphosphatase, sarcoplasmic reticulum, 137
carbaryl, pineal gland, indolamines, melatonin, serotonin, *N*-acetyltransferase activity, hydroxyindole-*O*-methyltransferase activity, 305
carcinogen, adduct, benzo[*a*]pyrene, chromatography, hemoglobin, in vitro metabolism, 109
chemical reactivity, inhalation, acrylonitrile, acrylic acid esters, total and non-protein sulfhydryls, blood glucose, 209
chromatography, adduct, benzo[*a*]pyrene, carcinogen, hemoglobin, in vitro metabolism, 109
clofibric acid, peroxisome, hepatocytes, lipid peroxidation, nafenopin, mono(2-ethylhexyl)-pthalate, 49
computer optimised molecular parametric analysis for chemical toxicity, benoxaprofen, cytochromes *P*450I and *P*450IV, quantitative structure-activity relationship, hepatotoxicity, phototoxicity, 33
copper, mercury, erythrocyte, spin labels, 315

cytochromes *P*450I and *P*450IV, benoxaprofen, computer optimised molecular parametric analysis for chemical toxicity quantitative structure-activity relationship, hepatotoxicity, phototoxicity, 33

delayed neurotoxicity, tri-*o*-cresyl phosphate, organophosphorus compound-induced delayed neurotoxicity, metabolism, rat, 61
desethylamiodarone, amiodarone, placental-transfer, fetotoxicity, birth weight, 259
di(2-ethylhexyl)phthalate, serum cholinesterase, serum arylesterase, serum triglycerides, serum cholesterol, peroxisome proliferation, 199
diabetes mellitus, aluminum, calcium, calmodulin, adenosine triphosphatase, sarcoplasmic reticulum, 137
diethyldithiocarbamate, cadmium, hepatocytes, lead, mercury, 23
distribution, cadmium-metallothionein, nephrotoxicity, pregnant rat, 223
disulfiram, lead, astrocytes, GFA, image analysis, brain development, 333
DNA damage, genotoxicity, mutagenicity, lithium hypochlorite, lithium, hypochlorite, 1
dose-response relationship, urinary cadmium, urinary metallothionein, urinary β_2-microglobulin, maximum alllowable concentration, 325
Drosophila, LD_{50}, strontium, second chromosome, 251

enzymuria, 3-amino-1-hydroxypropylidene-1,1-bisphosphonate, pamidronate, treatment of metabolic bone disorders, nephrotoxicity, pharmacokinetics, 179
epidermal growth factor receptors, 2,3,7,8,-tetrachlorodibenzo-*p*-dioxin, ethoxyresorufin-*O*-deethylase, glucocorticoid receptors, skin, hairless mice, 123
erythrocyte, copper, mercury, spin labels, 315
ethoxyresorufin-*O*-deethylase, 2,3,7,8,-tetrachlorodibenzo-*p*-dioxin, glucocorticoid receptors, epidermal growth factor receptors, skin, hairless mice, 123
experimental carcinogens, risk assessment, animals, low dose extrapolation, reproducibility, methylene chloride, 75

fetotoxicity, amiodarone, desethylamiodarone, placental-transfer, birth weight, 259

genotoxicity, mutagenicity, DNA damage, lithium hypochlorite, lithium, hypochlorite, 1
GFA, lead, disulfiram, astrocytes, image analysis, brain development, 333
glucocorticoid receptors, 2,3,7,8,-tetrachlorodibenzo-*p*-dioxin, ethoxyresorufin-*O*-deethylase, epidermal growth factor receptors, skin, hairless mice, 123
gluconeogenic precursors, cadmium, selenium, rat hepatocytes, 161
glutamine synthetase activity, astroglia, inorganic lead, lead-exposed rats, 295
glutathione*S*-transferase, buthionine sulfoximine, UDP-glucuronosyltransferases, induction, 149
guinea pig, hyperreactive airways, pulmonary hypersensitivity, histamine challenge, animal model, ovalbumin, 283

hairless mice, 2,3,7,8,-tetrachlorodibenzo-*p*-dioxin, ethoxyresorufin-*O*-deethylase, glucocorticoid receptors, epidermal growth factor receptors, skin, 123
hemoglobin, adduct, benzo[*a*]pyrene, carcinogen, chromatography, in vitro metabolism, 109
hepatocytes, cadmium, diethyldithiocarbamate, lead, mercury, 23
hepatocytes, peroxisome, lipid peroxidation, nafenopin, clofibric acid, mono(2-ethylhexyl)phthalate, 49
hepatotoxicity, benoxaprofen, cytochromes *P*450I and *P*450IV, computer optimised molecular parametric analysis for chemical toxicity quantitative structure-activity relationship, phototoxicity, 33
histamine challenge, hyperreactive airways, pulmonary hypersensitivity, animal model, guinea pig, ovalbumin, 283
hydroxyindole-*O*-methyltransferase activity, carbaryl, pineal gland, indolamines, melatonin, serotonin, *N*-acetyltransferase activity, 305
hyperreactive airways, pulmonary hypersensitivity, histamine challenge, animal model, guinea pig, ovalbumin, 283
hypochlorite, genotoxicity, mutagenicity, DNA damage, lithium hypochlorite, lithium, 1

image analysis, lead, disulfiram, astrocytes, GFA, brain development, 333
indolamines, carbaryl, pineal gland, melatonin, serotonin, *N*-acetyltransferase activity, hydroxyindole-*O*-methyltransferase activity, 305
induction, buthionine sulfoximine, UDP-glucuronosyltransferases, glutathione *S*-transferase, 149
inhalation, acrylonitrile, acrylic acid esters, total and non-protein sulfhydryls, blood glucose, chemical reactivity, 209
inhalation, solvent, *p*-xylene, lung, *P*-450, phospholipid, 271

inorganic lead, glutamine synthetase activity, astroglia, lead-exposed rats, 295
in vitro metabolism, adduct, benzo[*a*]pyrene, carcinogen, chromatography, hemoglobin, 109

LD_{50}, *Drosophila*, strontium, second chromosome, 251
lead, cadmium, diethyldithiocarbamate, hepatocytes, mercury, 23
lead, disulfiram, astrocytes, GFA, image analysis, brain development, 333
lead-exposed rats, glutamine synthetase activity, astroglia, inorganic lead, 295
lipid peroxidation, peroxisome, hepatocytes, nafenopin, clofibric acid, mono(2-ethylhexyl)-phthalate, 49
lithium, genotoxicity, mutagenicity, DNA damage, lithium hypochlorite, hypochlorite, 1
lithium hypochlorite, genotoxicity, mutagenicity, DNA damage, lithium, hypochlorite, 1
lowest observed adverse effect level, methacrylonitrile, toxicity, metabolism, no observed adverse effect level, 239
low dose extrapolation, risk assessment, experimental carcinogens, animals, reproducibility, methylene chloride, 75
lung, solvent, *p*-xylene, inhalation, *P*-450, phospholipid, 271

maximum alllowable concentration, dose-response relationship, urinary cadmium, urinary metallothionein, urinary β_2-microglobulin, 325
melatonin, carbaryl, pineal gland, indolamines, serotonin, *N*-acetyltransferase activity, hydroxyindole-*O*-methyltransferase activity, 305
mercury, cadmium, diethyldithiocarbamate, hepatocytes, lead, 23
mercury, copper, erythrocyte, spin labels, 315
metabolism, methacrylonitrile, toxicity, no observed adverse effect level, lowest observed adverse effect level, 239
metabolism, tri-*o*-cresyl phosphate, organophosphorus compound-induced delayed neurotoxicity, rat, delayed neurotoxicity, 61
metallothionein, osteosarcoma cells, cadmium, ROS 117/2.8 cells, 169
methacrylonitrile, toxicity, metabolism, no observed adverse effect level, lowest observed adverse effect level, 239
methylene chloride, risk assessment, experimental carcinogens, animals, low dose extrapolation, reproducibility, 75
mono(2-ethylhexyl)phthalate, peroxisome, hepatocytes, lipid peroxidation, nafenopin, clofibric acid, 49
mutagenicity, genotoxicity, DNA damage, lithium hypochlorite, lithium, hypochlorite, 1

N-acetyltransferase activity, carbaryl, pineal gland, indolamines, melatonin, serotonin, hydroxyindole-*O*-methyltransferase activity, 305
nafenopin, peroxisome, hepatocytes, lipid peroxidation, clofibric acid, mono(2-ethylhexyl)-phthalate, 49
nephrotoxicity, 3-amino-1-hydroxypropylidene-1,1-bisphosphonate, pamidronate, treatment of metabolic bone disorders, pharmacokinetics, enzymuria, 179
nephrotoxicity, cadmium-metallothionein, distribution, pregnant rat, 223
no observed adverse effect level, methacrylonitrile, toxicity, metabolism, lowest observed adverse effect level, 239

organophosphorus compound-induced delayed neurotoxicity, tri-*o*-cresyl phosphate, metabolism, rat, delayed neurotoxicity, 61
osteosarcoma cells, cadmium, ROS 117/2.8 cells, metallothionein, 169
ovalbumin, hyperreactive airways, pulmonary hypersensitivity, histamine challenge, animal model, guinea pig, 283

P-450, solvent, *p*-xylene, inhalation, lung, phospholipid, 271
p-xylene, solvent, inhalation, lung, *P*-450, phospholipid, 271
pamidronate, 3-amino-1-hydroxypropylidene-1,1-bisphosphonate, treatment of metabolic bone disorders, nephrotoxicity, pharmacokinetics, enzymuria, 179
peroxisome, hepatocytes, lipid peroxidation, nafenopin, clofibric acid, mono(2-ethylhexyl)-phthalate, 49
peroxisome proliferation, di(2-ethylhexyl)-phthalate, serum cholinesterase, serum arylesterase, serum triglycerides, serum cholesterol, 199
pharmacokinetics, 3-amino-1-hydroxypropylidene-1,1-bisphosphonate, pamidronate, treatment of metabolic bone disorders, nephrotoxicity, enzymuria, 179
phospholipid, solvent, *p*-xylene, inhalation, lung, *P*-450, 271
phototoxicity, benoxaprofen, cytochromes *P*450I and *P*450IV, computer optimised molecular parametric analysis for chemical toxicity, quantitative structure-activity relationship, hepatotoxicity, 33
pineal gland, carbaryl, indolamines, melatonin,

serotonin, *N*-acetyltransferase activity, hydroxyindole-*O*-methyltransferase activity, 305
placental-transfer, amiodarone, desethylamiodarone, fetotoxicity, birth weight, 259
pregnant rat, cadmium-metallothionein, nephrotoxicity, distribution, 223
pulmonary hypersensitivity, hyperreactive airways, histamine challenge, animal model, guinea pig, ovalbumin, 283

quantitative structure-activity relationship, benoxaprofen, cytochromes *P*450I and *P*450IV, computer optimised molecular parametric analysis for chemical toxicity, hepatotoxicity, phototoxicity, 33

rat, tri-*o*-cresyl phosphate, organophosphorus compound-induced delayed neurotoxicity, metabolism, delayed neurotoxicity, 61
rat hepatocytes, cadmium, selenium, gluconeogenic precursors, 161
reproducibility, risk assessment, experimental carcinogens, animals, low dose extrapolation, methylene chloride, 75
risk assessment, experimental carcinogens, animals, low dose extrapolation, reproducibility, methylene chloride, 75
ROS 117/2.8 cells, osteosarcoma cells, cadmium, metallothionein, 169

sarcoplasmic reticulum, diabetes mellitus, aluminum, calcium, calmodulin, adenosine triphosphatase, 137
second chromosome, *Drosophila*, LD_{50}, strontium, 251
selenium, cadmium, gluconeogenic precursors, rat hepatocytes, 161
serotonin, carbaryl, pineal gland, indolamines, melatonin, *N*-acetyltransferase activity, hydroxyindole-*O*-methyltransferase activity, 305
serum arylesterase, di(2-ethylhexyl)phthalate, serum cholinesterase, serum triglycerides, serum cholesterol, peroxisome proliferation, 199
serum cholesterol, di(2-ethylhexyl)phthalate, serum cholinesterase, serum arylesterase, serum triglycerides, peroxisome proliferation, 199
serum cholinesterase, di(2-ethylhexyl)phthalate, serum arylesterase, serum triglycerides, serum cholesterol, peroxisome proliferation, 199
serum triglycerides, di(2-ethylhexyl)phthalate, serum cholinesterase, serum arylesterase, serum cholesterol, peroxisome proliferation, 199
skin, 2,3,7,8,-tetrachlorodibenzo-*p*-dioxin, ethoxyresorufin-*O*-deethylase, glucocorticoid receptors, epidermal growth factor receptors, hairless mice, 123
solvent, *p*-xylene, inhalation, lung, *P*-450, phospholipid, 271
species differences, 2,3,7,8,-tetrachlorodibenzo-*p*-dioxin, acute toxicity, total body fat content, 97
spin labels, copper, mercury, erythrocyte, 315
strontium, *Drosophila*, LD_{50}, second chromosome, 251

2,3,7,8,-tetrachlorodibenzo-*p*-dioxin, ethoxyresorufin-*O*-deethylase, glucocorticoid receptors, epidermal growth factor receptors, skin, hairless mice, 123
2,3,7,8,-tetrachlorodibenzo-*p*-dioxin, acute toxicity, species differences, total body fat content, 97
total and non-protein sulfhydryls, inhalation, acrylonitrile, acrylic acid esters, blood glucose, chemical reactivity, 209
total body fat content, 2,3,7,8,-tetrachlorodibenzo-*p*-dioxin, acute toxicity, species differences, 97
toxicity, methacrylonitrile, metabolism, no observed adverse effect level, lowest observed adverse effect level, 239
treatment of metabolic bone disorders, 3-amino-1-hydroxypropylidene-1,1-bisphosphonate, pamidronate, nephrotoxicity, pharmacokinetics, enzymuria, 179
tri-*o*-cresyl phosphate, organophosphorus compound-induced delayed neurotoxicity, metabolism, rat, delayed neurotoxicity, 61

UDP-glucuronosyltransferases, buthionine sulfoximine, glutathione*S*-transferase, induction, 149
urinary β_2-microglobulin, dose-response relationship, urinary cadmium, urinary metallothionein, maximum alllowable concentration, 325
urinary cadmium, dose-response relationship, urinary metallothionein, urinary β_2-microglobulin, maximum alllowable concentration, 325
urinary metallothionein, dose-response relationship, urinary cadmium, urinary β_2-microglobulin, maximum alllowable concentration, 325

Toxicology 65 (1991) 357—358
Elsevier Scientific Publishers Ireland Ltd.

TOXICOLOGY

AUTHOR INDEX

Volume 65

Abbott, B.D. 123
Abou-Donia, M.B. 61
Abreo, K. 137
Angle, C.R. 169
Attia, A.M. 305

Ban, M. 223
Batt, K.J. 1
Bell, R.R. 161
Beydon, D. 223
Birnbaum, L.S. 123
Bjorklund, H. 333
Bower, J.H. 61
Bucchi, A.R. 75

Cal, J.-C. 179
Curren, R.D. 1

Daley-Yates, P.T. 179
de Ceaurriz, J. 223
Dirven, H.A.A.M. 199

Early, J.L.,II 161
El-Sebae, A.H. 305
England, M.W. 251

Farooqui, M.Y.H. 239
Faust, J.B. 251
Franklin, M.R. 149
Frantík, E. 209

Geyer, H.J. 97
Greim, H. 97
Griffiths-Johnson, D.A. 283
Gut, I. 209
Gwozdzinski, K. 315

Haugen, D.A. 109
Heindel, S.W. 49
Hellström-Lindahl E. 23
Henschen, A. 333
Hill, D.A. 259
Hoffer, B. 333
Honda R. 325

Ioannides, C. 33

Jacobson, K.B. 251
Jenkins, W.L. 49
Jongeneelen, F.J. 199

Karol, M.H. 283
Kettrup, A. 97
Kido, T. 325
Kito H. 325
Korte, F. 97

Levine, S.N. 137
Lewis, D.F.V. 33
Lin, F.H. 123
Loizzo, A. 75
Luthman, J. 333

Makkawy, H.A. 61
Manning, B.W. 149
Melnick, R.L. 49
Mostafa, M.H. 305
Mumtaz, M.M. 239

Nogawa K. 325
Nomeir, A.A. 61
Nonaka, K.O. 305

Olson, L. 333
Oskarsson, A. 23
Oskarsson, A. 333

Parke, D.V. 33
Payan, J.P. 223
Putman, D.L. 1

Rapp, K. 97
Reasor, M.J. 259
Reiter, R.J. 305
Rozman, K. 97

Saillenfait, A.M. 223
Schatz, R.A. 271
Scheuntert, I. 97

Shaikh Z.A. 325
Sierra, E.M. 295
Silverman, D.M. 271
Soliman S.A. 305
Soliman, M.R.I. 161
Sonnier, G.B. 137
Stohs, S.J. 123
Swanson, S.A. 169

Thomas, D.J 169
Tiffany-Castiglioni, E. 295
Tomaszewski, K.E. 49

van den Broek, P.H.H. 199
Vodicka, P. 209

Weiner, M.L. 1
Wilkerson, E.K. 251

Yang, L.L. 1

Zapponi, G.A. 75
Zegar, I.S. 109